Ainos Completes Stock Consolidation, Enters New Phase of Global Expansion and Technology Commercialization
Ainos (NASDAQ:AIMD) has completed a 1-for-5 stock consolidation effective June 30, 2025, while announcing significant progress in its AI-powered olfactory intelligence business. The company is targeting the electronic nose market, projected to grow from $29.8 billion in 2025 to $76.5 billion by 2032.
The company has established key partnerships for AI Nose deployment: ASE Technology Holding (planning deployment of 1,400 units in pilot phase, scaling to 5,000 in Phase 1 and 15,000 in Phase 2), Kenmec Mechanical Engineering for smart factory integration, and ugo for robotics applications in Japan. In Q1 2025, Ainos reported a 412% year-over-year revenue growth.
The company's Smell Language Model (SLM) has achieved over 90% accuracy in classifying meat, food, and beverage samples. In the senior care sector, their technology demonstrated 85%+ accuracy in hygiene detection across 2,000+ samples. Additionally, Ainos is advancing clinical trials for VELDONA® in Taiwan for HIV-related oral warts and Sjögren's syndrome.
Ainos (NASDAQ:AIMD) ha completato un consolidamento azionario 1-per-5 con effetto dal 30 giugno 2025, annunciando al contempo notevoli progressi nel suo business di intelligenza olfattiva basata sull'IA. L'azienda punta al mercato del naso elettronico, previsto in crescita da 29,8 miliardi di dollari nel 2025 a 76,5 miliardi di dollari entro il 2032.
Ha stretto partnership strategiche per l'implementazione dell'AI Nose: ASE Technology Holding (con un piano di distribuzione di 1.400 unità nella fase pilota, espandendosi a 5.000 nella Fase 1 e 15.000 nella Fase 2), Kenmec Mechanical Engineering per l'integrazione nelle smart factory, e ugo per applicazioni robotiche in Giappone. Nel primo trimestre 2025, Ainos ha registrato una crescita del fatturato del 412% su base annua.
Il modello linguistico olfattivo dell'azienda (Smell Language Model - SLM) ha raggiunto una precisione superiore al 90% nella classificazione di campioni di carne, alimenti e bevande. Nel settore dell'assistenza agli anziani, la tecnologia ha dimostrato una accuratezza superiore all'85% nel rilevamento dell'igiene su oltre 2.000 campioni. Inoltre, Ainos sta portando avanti studi clinici per VELDONA® a Taiwan, mirati a verruche orali correlate all'HIV e alla sindrome di Sjögren.
Ainos (NASDAQ:AIMD) ha completado una consolidación de acciones 1 por 5 con efecto a partir del 30 de junio de 2025, mientras anuncia avances significativos en su negocio de inteligencia olfativa impulsada por IA. La compañía apunta al mercado de narices electrónicas, que se proyecta crecer de 29,8 mil millones de dólares en 2025 a 76,5 mil millones para 2032.
Ha establecido asociaciones clave para el despliegue del AI Nose: ASE Technology Holding (planeando desplegar 1,400 unidades en fase piloto, escalando a 5,000 en la Fase 1 y 15,000 en la Fase 2), Kenmec Mechanical Engineering para integración en fábricas inteligentes, y ugo para aplicaciones robóticas en Japón. En el primer trimestre de 2025, Ainos reportó un crecimiento de ingresos interanual del 412%.
El Modelo de Lenguaje Olfativo (Smell Language Model - SLM) de la empresa ha alcanzado una precisión superior al 90% en la clasificación de muestras de carne, alimentos y bebidas. En el sector de cuidado de personas mayores, su tecnología demostró una precisión superior al 85% en la detección de higiene en más de 2,000 muestras. Además, Ainos está avanzando en ensayos clínicos para VELDONA® en Taiwán para verrugas orales relacionadas con el VIH y el síndrome de Sjögren.
Ainos (NASDAQ:AIMD)는 2025년 6월 30일부로 1대 5 주식 병합을 완료했으며, AI 기반 후각 인텔리전스 사업에서 중요한 진전을 발표했습니다. 회사는 2025년 298억 달러에서 2032년 765억 달러로 성장할 것으로 예상되는 전자 코 시장을 목표로 하고 있습니다.
AI 코 배치를 위해 주요 파트너십을 구축했습니다: 파일럿 단계에서 1,400대 배치를 계획 중인 ASE Technology Holding, 스마트 팩토리 통합을 위한 Kenmec Mechanical Engineering, 일본에서 로봇 응용을 위한 ugo. 2025년 1분기 Ainos는 전년 대비 412% 매출 성장을 보고했습니다.
회사의 후각 언어 모델(Smell Language Model, SLM)은 고기, 식품, 음료 샘플 분류에서 90% 이상의 정확도를 달성했습니다. 노인 돌봄 분야에서는 2,000개 이상의 샘플에서 위생 감지 정확도가 85% 이상임을 입증했습니다. 또한 Ainos는 대만에서 HIV 관련 구강 사마귀 및 쇼그렌 증후군 치료를 위한 VELDONA® 임상 시험을 진행 중입니다.
Ainos (NASDAQ:AIMD) a finalisé une consolidation d’actions au ratio de 1 pour 5, effective au 30 juin 2025, tout en annonçant des progrès significatifs dans son activité d’intelligence olfactive alimentée par l’IA. L’entreprise cible le marché du nez électronique, dont la valeur est projetée passer de 29,8 milliards de dollars en 2025 à 76,5 milliards d’ici 2032.
Elle a établi des partenariats clés pour le déploiement de l’AI Nose : ASE Technology Holding (prévoit de déployer 1 400 unités lors de la phase pilote, avec une montée en charge à 5 000 en phase 1 et 15 000 en phase 2), Kenmec Mechanical Engineering pour l’intégration en usine intelligente, et ugo pour des applications robotiques au Japon. Au premier trimestre 2025, Ainos a enregistré une croissance de chiffre d’affaires de 412 % sur un an.
Le modèle linguistique olfactif (Smell Language Model - SLM) de la société a atteint une précision supérieure à 90 % dans la classification d’échantillons de viande, d’aliments et de boissons. Dans le secteur des soins aux personnes âgées, leur technologie a démontré une précision supérieure à 85 % dans la détection d’hygiène sur plus de 2 000 échantillons. De plus, Ainos fait progresser des essais cliniques pour VELDONA® à Taïwan concernant les verrues orales liées au VIH et le syndrome de Sjögren.
Ainos (NASDAQ:AIMD) hat zum 30. Juni 2025 eine Aktienzusammenlegung im Verhältnis 1 zu 5 abgeschlossen und gleichzeitig bedeutende Fortschritte in seinem KI-gestützten olfaktorischen Intelligenzgeschäft bekannt gegeben. Das Unternehmen zielt auf den Markt für elektronische Nasen ab, der von 29,8 Milliarden US-Dollar im Jahr 2025 auf 76,5 Milliarden US-Dollar bis 2032 wachsen soll.
Es wurden wichtige Partnerschaften für den Einsatz der AI Nose geschlossen: ASE Technology Holding (geplant sind 1.400 Einheiten in der Pilotphase, mit einer Skalierung auf 5.000 in Phase 1 und 15.000 in Phase 2), Kenmec Mechanical Engineering für die Integration in Smart Factories und ugo für Robotikanwendungen in Japan. Im ersten Quartal 2025 verzeichnete Ainos ein Umsatzwachstum von 412 % im Jahresvergleich.
Das Smell Language Model (SLM) des Unternehmens erreichte eine Genauigkeit von über 90 % bei der Klassifizierung von Fleisch-, Lebensmittel- und Getränkemustern. Im Bereich der Seniorenbetreuung zeigte die Technologie eine Genauigkeit von über 85 % bei der Hygienedetektion an mehr als 2.000 Proben. Zudem führt Ainos klinische Studien für VELDONA® in Taiwan für HIV-bedingte orale Warzen und das Sjögren-Syndrom durch.
- 412% year-over-year revenue growth in Q1 2025
- Strategic partnership with ASE Technology for potential deployment of up to 15,000 AI Nose units
- SLM technology achieved over 90% accuracy in food classification
- 85%+ accuracy demonstrated in senior care hygiene detection across 2,000+ samples
- Stock consolidation strengthens capital structure and maintains Nasdaq listing compliance
- None.
Insights
Ainos' stock consolidation positions it to commercialize AI-powered smell technology amid substantial market growth, with promising partnerships and revenue potential.
Ainos' 1-for-5 stock consolidation marks a strategic financial restructuring aimed at strengthening its capital structure while maintaining Nasdaq compliance. This move doesn't change ownership percentages but potentially makes the stock more attractive to institutional investors by elevating the share price.
The company is targeting the electronic nose market, projected to grow from
The partnership with ASE Technology Holding appears particularly significant, featuring a multi-stage deployment roadmap starting with 1,400 units for field testing, potentially scaling to 5,000 units in Phase 1 and up to 15,000 units in Phase 2. This structured approach suggests a methodical commercialization strategy rather than speculative projections.
The
While the technology shows promise across multiple verticals, the semiconductor manufacturing partnership with ASE likely represents the most immediate revenue opportunity given the defined deployment roadmap. The business model appears to combine hardware sales with recurring revenue from sensing data services, potentially creating stable revenue streams if successfully executed.
Partners With ASE to Scale AI Nose Deployment and Set New Standard in Intelligent Sensing
Achieves Strategic Inflection Point in 1H 2025 with Partnerships and Operational Breakthroughs
SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 30, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company") today announced the completion of a 1-for-5 stock consolidation, effective at the opening of trading on June 30, 2025. The move strengthens the Company's capital structure, aligns with Nasdaq listing requirements, and positions Ainos to scale global commercial operations across its AI Nose platforms.
"Ainos is defining the future of olfactory intelligence," said Eddy Tsai, Chairman, President and CEO of Ainos. "The global electronic nose market is expected to grow from
Second-Half 2025: Commercial Execution and Business Expansion
Following a pivotal first half, Ainos is focused on executing across strategic pillars:
Semiconductor Manufacturing with ASE - Pursue a multi-stage AI Nose rollout roadmap with ASE Technology Holding, beginning with approximately 1,400 units of AI Nose for field pilot, laying foundation to scale deployment to approximately 5,000 units Phase 1 and up 15,000 units in Phase 2, enabling next-generation VOC detection.
Smart Factories in Asia with Kenmec - Plan scaling AI Nose and SLM into Kenmec Mechanical Engineering's smart factory ecosystem, accelerating deployment of multimodal sensory intelligence across robotics, logistics and autonomous manufacturing.
Robotics with ugo - Advance AI Nose field pilots in Japan with ugo for the world's first service robot equipped with a sense of smell; begin field test across Japanese infrastructure sites, targeting utility, maintenance and airport scenarios.
Senior care - Initiate large-scale AI Nose pilot deployment with partners in Japan; evaluate Taiwan opportunities.
VELDONA® Clinical Pipeline - Initiate human clinical trials in Taiwan for HIV-related oral warts and Sjögren's syndrome following recent regulatory approval; continue veterinary trials for FCGS.
Smell Language Model (SLM) - Expand the proprietary scent dataset powering the smell language model (SLM), Ainos' AI architecture that transforms scent into machine-readable Smell ID. The platform has achieved over
90% accuracy in classifying meat, food, and beverage samples, and is now being commercialized across industrial and healthcare settings.
"Smell language model (SLM) will be how we give machines the ability to understand the environment through scent and it's core to the next wave of sensory AI, a key extension from vision and hearing" Eddy commented. "We see tremendous potential in cleanroom, ESG, smart healthcare, smart factory and automation."
Capital Structure Aligned for Growth
The 1-for-5 stock consolidation reduces Ainos' outstanding shares while proportionally increasing share price. Shareholder ownership percentages remain unchanged. The action enhances the Company's readiness for institutional participation and supports its transition into recurring-revenue operations.
First-Half 2025: Strategic Inflection Point Achieved
Ainos' strong first-half performance sets the stage for accelerated second-half execution:
Semiconductor Partnership - Initiated partnership with ASE to explore AI Nose deployment across its key manufacturing networks with 56 smart factories.
Robotic Integration - Completed software-hardware integration of AI Nose into ugo's robots, initiating field pilots in Japan.
Smart Factory Collaboration - Partnered with Kenmec for manufacturing and deployment of AI Nose in smart factory systems across Asia.
Senior Care Validation - Achieved
85% + accuracy in scent-based hygiene detection across over 2,000 samples in Japan's elderly care sector; further scaling expected in Japan and Taiwan.Smell ID Expansion - Continued development of proprietary scent database and SLM training models for multi-industry application.
Q1 Revenue Surge - Reported
412% YoY revenue growth, driven by initial AI Nose deployments in senior care pilots.
"Our strategy is clear: building a new sensory layer with AI Nose. We're turning smelltech into an emerging AI infrastructure," Eddy added. "Looking ahead, we'll continue to build strategic relationships across industries and geographies to accelerate adoption of our AI Nose platform and smell language model (SLM). This is just the beginning. Ainos is focused, positioned for scale, and committed to leading the AI-powered SmellTech economy."
About Ainos, Inc.
Ainos, Inc. (NASDAQ: AIMD) is a dual-platform AI and biotech company pioneering SmellTech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA®, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. Ainos, a fusion of "AI" and "Nose," is redefining machine perception for the sensory age. To learn more, visit https://www.ainos.com. Follow Ainos on X (@AinosInc) and LinkedIn for updates.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management's current assumptions and expectations of future events and trends, which affect or may affect the Company's business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, our expectation that we will incur net losses for the foreseeable future; our ability to become profitable; our ability to raise additional capital to continue our product development; our ability to accurately predict our future operating results; our ability to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize any product candidates we develop; the ability to obtain and maintain regulatory approval of our product candidates; delays in completing the development and commercialization of our current and future product candidates; developing and commercializing additional products, including diagnostic testing devices; our ability to compete in the marketplace; compliance with applicable laws, regulations and tariffs, and factors described in the Risk Factors section of our public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
Contact Information
Feifei Shen
ir@ainos.com
SOURCE: Ainos, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the ratio of Ainos (NASDAQ:AIMD) stock consolidation in 2025?
How many AI Nose units will Ainos deploy with ASE Technology?
What was Ainos' revenue growth in Q1 2025?
What is the projected size of the electronic nose market by 2032?
What accuracy rate has Ainos' Smell Language Model (SLM) achieved?
What clinical trials is Ainos initiating in Taiwan?
